CN1703199B - 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用 - Google Patents

具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用 Download PDF

Info

Publication number
CN1703199B
CN1703199B CN2003801013013A CN200380101301A CN1703199B CN 1703199 B CN1703199 B CN 1703199B CN 2003801013013 A CN2003801013013 A CN 2003801013013A CN 200380101301 A CN200380101301 A CN 200380101301A CN 1703199 B CN1703199 B CN 1703199B
Authority
CN
China
Prior art keywords
aggregation
formulation
component
mdc
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2003801013013A
Other languages
English (en)
Chinese (zh)
Other versions
CN1703199A (zh
Inventor
格雷戈尔·塞维克
乌尔里克·维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idea AG
Original Assignee
Idea AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/357,618 external-priority patent/US20040105881A1/en
Application filed by Idea AG filed Critical Idea AG
Publication of CN1703199A publication Critical patent/CN1703199A/zh
Application granted granted Critical
Publication of CN1703199B publication Critical patent/CN1703199B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2003801013013A 2002-10-11 2003-10-09 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用 Expired - Fee Related CN1703199B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41784702P 2002-10-11 2002-10-11
US60/417,874 2002-10-11
US10/357,618 US20040105881A1 (en) 2002-10-11 2003-02-04 Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US10/357,618 2003-02-04
US10/357,617 US7473432B2 (en) 2002-10-11 2003-02-04 NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US10/357,617 2003-02-04
PCT/EP2003/011202 WO2004032900A1 (en) 2002-10-11 2003-10-09 Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201010114833A Division CN101862295A (zh) 2002-10-11 2003-10-09 具有增强的可变形性、包含至少三种两亲性物质的聚集物

Publications (2)

Publication Number Publication Date
CN1703199A CN1703199A (zh) 2005-11-30
CN1703199B true CN1703199B (zh) 2010-04-28

Family

ID=32995875

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2003801013013A Expired - Fee Related CN1703199B (zh) 2002-10-11 2003-10-09 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用

Country Status (21)

Country Link
EP (5) EP1815846A3 (enExample)
JP (3) JP2006505619A (enExample)
KR (1) KR20050055723A (enExample)
CN (1) CN1703199B (enExample)
AT (1) ATE381316T1 (enExample)
AU (1) AU2003273977B2 (enExample)
BR (1) BR0315148A (enExample)
CA (1) CA2498938A1 (enExample)
DE (1) DE60318227T2 (enExample)
DK (1) DK1551370T3 (enExample)
EA (1) EA010407B1 (enExample)
ES (1) ES2298566T3 (enExample)
HR (1) HRPK20050421B3 (enExample)
IS (1) IS7776A (enExample)
MX (1) MXPA05003744A (enExample)
NO (1) NO20052281L (enExample)
NZ (1) NZ538571A (enExample)
PL (1) PL377202A1 (enExample)
PT (1) PT1551370E (enExample)
SI (1) SI1551370T1 (enExample)
WO (1) WO2004032900A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
EP1031347B1 (en) 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
CA2698293A1 (en) * 2007-09-13 2009-03-26 Thomas Subkowski Use of hydrophobin polypeptides as penetration intensifiers
PL214538B1 (pl) * 2009-05-28 2013-08-30 P P F Hasco Lek Spolka Akcyjna Kompozycja liposomowa zawierajaca naproksen i sposób wytwarzania kompozycji liposomowej zawierajacej naproksen
JP2012528846A (ja) * 2009-06-03 2012-11-15 マヨ、ジョン、チャールズ 深部組織の痛みを治療するための製剤
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
EP2688554A2 (en) * 2011-03-21 2014-01-29 Gregor Cevc Optimised preparations of highly adaptable aggregates
US20140017301A1 (en) * 2011-03-21 2014-01-16 Gregor Cevc Drug-free compositions and methods for diminishing peripheral inflammation and pain
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
JP6375301B2 (ja) * 2012-10-26 2018-08-15 オックスフォード ナノポール テクノロジーズ リミテッド 液滴界面
RU2524649C1 (ru) * 2013-07-24 2014-07-27 Станислав Анатольевич Кедик Способ получения микросфер для приготовления инъецируемой лекарственной формы диклофенака, композиция и лекарственная форма
SG11201600424VA (en) * 2013-07-31 2016-02-26 Sequessome Technology Holdings Ltd Vesicles
CN105764917B (zh) * 2013-09-26 2021-10-08 新加坡国立大学 利用溶血磷脂酰胆碱支架的组合物和方法
CN105658782B (zh) * 2013-10-25 2018-08-07 凸版印刷株式会社 膜囊泡回收设备、膜囊泡回收方法及膜囊泡分析方法
US10744090B2 (en) 2015-06-30 2020-08-18 Sequessome Technology Holdings Limited Multiphasic compositions
EP3377043A4 (en) 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
CN110662532A (zh) * 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102149190B1 (ko) 2018-04-09 2020-08-28 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
KR102209397B1 (ko) 2020-07-21 2021-01-29 경상대학교산학협력단 액중 방전 마이크로젯 약물 전달장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3765579B2 (ja) * 1990-08-24 2006-04-12 イーデーエーアー アーゲー 作用物質投与用超微小滴状調剤
DE4107153A1 (de) * 1991-03-06 1992-09-10 Gregor Cevc Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
CZ20012038A3 (cs) * 1998-12-23 2001-09-12 Idea Ag Zdokonalený přípravek pro topické, neinvazivní použití in vivo
EP1031347B1 (en) * 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers

Also Published As

Publication number Publication date
ATE381316T1 (de) 2008-01-15
EP1815846A2 (en) 2007-08-08
NO20052281L (no) 2005-07-07
JP2006505619A (ja) 2006-02-16
JP2005213261A (ja) 2005-08-11
NO20052281D0 (no) 2005-05-10
NZ538571A (en) 2007-05-31
EP1829527A2 (en) 2007-09-05
HK1079113A1 (en) 2006-03-31
ES2298566T3 (es) 2008-05-16
EA200500632A1 (ru) 2005-12-29
IS7776A (is) 2005-03-30
BR0315148A (pt) 2005-08-16
EP1829527A3 (en) 2008-11-05
MXPA05003744A (es) 2005-09-20
HRPK20050421B3 (en) 2007-06-30
EA010407B1 (ru) 2008-08-29
PT1551370E (pt) 2008-02-07
PL377202A1 (pl) 2006-01-23
DE60318227T2 (de) 2008-12-04
EP1551370B1 (en) 2007-12-19
JP4555111B2 (ja) 2010-09-29
CA2498938A1 (en) 2004-04-22
EP1815847A2 (en) 2007-08-08
DE60318227D1 (de) 2008-01-31
EP1551370A1 (en) 2005-07-13
HRP20050421A2 (en) 2005-12-31
AU2003273977B2 (en) 2007-07-12
KR20050055723A (ko) 2005-06-13
WO2004032900A8 (en) 2005-03-31
CN1703199A (zh) 2005-11-30
DK1551370T3 (da) 2008-03-03
EP1829528A2 (en) 2007-09-05
AU2003273977A1 (en) 2004-05-04
SI1551370T1 (sl) 2008-06-30
EP1829528A3 (en) 2008-11-05
EP1815847A3 (en) 2008-11-05
WO2004032900A1 (en) 2004-04-22
EP1815846A3 (en) 2008-10-22
JP2009108070A (ja) 2009-05-21

Similar Documents

Publication Publication Date Title
JP4555111B2 (ja) 半透性バリアを介した向上した輸送のための、およびインビボでの、特に皮膚を介した非侵襲性薬剤利用のための、少なくとも３つの両親媒性物質を含む、向上した変形性を備えた凝集体
CN101862295A (zh) 具有增强的可变形性、包含至少三种两亲性物质的聚集物
RU2505291C2 (ru) Топическая композиция, содержащая ибупрофен
MX2014012198A (es) Formulaciones vesiculares para su uso en el tratamiento del dolor o movilidad reducida de una articulacion.
US20250134811A1 (en) Ultraflexible liposomes in gel formulation
HK1149499A (en) Aggregate with increased deformability, comprising at least three amphipats
HK1079113B (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
HK1104967A (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
Chadha Design, Optimization and Evaluation of a Novel Emulgel of Ibuprofen for Enhanced Skin Delivery using Formulating for Efficacy™ software
HK1104966A (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
HK1110504A (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
HK1110505A (en) Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100428

Termination date: 20121009